

Dapagliflozin and Diuretic Utilization in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial

Safia Chatur, MD on behalf of:

Muthiah Vaduganathan, MD, MPH, Brian Claggett, PhD, Orly Vardeny, PharmD MS, Akshay S. Desai, MD, MPH, Pardeep S. Jhund, MBChB, MSc, PhD, Rudolf A. de Boer, MD, Carolyn S.P Lam, MD, Mikhail N. Kosiborod, MD, Sanjiv J. Shah, MD, Felipe Martinez, MD, Silvio E. Inzucchi, MD, Adrian F Hernandez, MD, Tariq Haddad, MD, Sumeet S. Mitter, MD, MSc, Zi Michael Miao, MS, Magnus Petersson, MD, Anna Maria Langkilde, MD, John J. V. McMurray, MD, Scott D. Solomon, MD




@safchat

Heart Failure
& World Congress on
Acute Heart Failure
2023



Background


- SGLT2i = therapeutic pillar in HF
- SGLT2i promote early natriuresis and diuresis
?→ clinical benefits
- Diuretics are a cornerstone in HF management and concurrent use with SGLT2i will be frequent.
- Understanding the interplay between SGLT2i and conventional diuretics is important



Objectives:

- 1) Assess the **efficacy and safety** of dapagliflozin according to **background diuretic use** and dosing
- 2) Evaluate the effect of dapagliflozin on post-randomization **changes in diuretic use**


DELIVER Population:
NYHA II-IV, LVEF>40%, + structural heart disease, ↑ NP



1° Outcome
Worsening HF or CV Death

HR 0.82; $p < 0.001$
95% CI 0.73-0.92






Baseline Diuretic Use in DELIVER



Efficacy and Safety of Dapagliflozin By Diuretic Use and Dose


Consistent treatment effect:

No significant differences in safety outcomes:




Influence of Dapagliflozin on Loop Diuretic Use in Follow up


A: New Loop Diuretic Initiations Among Baseline Non-Users




B: Loop Diuretic Discontinuations Among Baseline Users



C: First Sustained Loop Diuretic Dose Change



D: Mean Loop Diuretic Dose Over Time



Conclusions

- 1) Treatment with dapagliflozin exhibited **consistent clinical benefits and safety profile** across a broad range of **diuretic use** categories and doses
- 2) Dapagliflozin significantly **reduced loop diuretic requirement over time** (difference emerging >day 60)
- 3) Differences were **driven by lower need for diuretic intensification** with **limited differences in** the necessity for loop **diuretic discontinuation** or dose reduction between treatment arms.

Simultaneously Published

**European
Heart Journal**



Available online at:

academic.oup.com/eurheartj
delivertrial.org

Take Home Point: Dapagliflozin leads to lower diuretic use over time consistent with an effect to reduce HF progression; however, these data argue against anticipatory loop diuretic dose reduction at the time of dapagliflozin initiation